(a) Western blot of CK1α levels after treatment of KG-1α cells with lenalidomide in the presence or absence of SB-405483 for 24 h. (a) Quantification of n = 3 biologically independent replicates of b. (c) Western blot of CK1α levels after treatment of MOLM-13 cells with increasing concentration of DEG-47 in the presence or absence of SB-405483 for 24 h. (d) Protein expression levels of CK1α after treatment with indicated compounds in MOLM-13 cells for 24 h (n = 3 biologically independent replicates). (e) Flow cytometry analysis of GFP levels in HEK293T cells expressing GFP-CK1α after treatment with DEG-47 in the presence and absence of SB-405483 for 24 h. (f) Western blot of CK1α levels after MOLM-13 treatment with DEG-47 with and without SB-405483 at various time points. (g) Quantification of CK1α levels after MOLM-13 treatment with DEG-47 in the presence or absence of SB-405483 at various time points. (h) Cell viability (MTT) assay of the indicated compounds after treatment of MOLM-13 cells for 3 d. (i) Western blot analysis of CK1α levels after treatment of MOLM-13 CK1α WT and MOLM-13 CK1α G40N cells with 1 µM DEG-47 for 24 h. (j) Structure of DEG-35. (k) Western blot of CK1α levels after RAW 264.7 treatment with DEG-35 in the presence or absence of SB-405483 for 3 h. (l) Quantification of n = 3 biologically independent samples of k. Comparisons were performed using a one-way ANOVA with Šídák’s multiple comparisons test. P-values are shown. Data are represented as mean ± SD. Western blot, cell viability, and flow cytometry data are representative of n = 3 biologically independent samples. For uncropped Western blot images, see Supplementary Fig. 3.
Source data